Abstract:The introduction of continuous glucose monitoring (CGM) systems in clinical practice has allowed a more detailed picture of the intra- and interdaily glycemic fluctuations of individuals with type 1 diabetes (T1D). However, CGM-measured glucose control indicators may be occasionally inaccurate. This study aims to assess the discrepancy between the glucose management indicator (GMI) and glycated hemoglobin (HbA1c) (ΔGMI-HbA1c) within a cohort of children and adolescents with T1D, exploring its correlation with other CGM metrics and blood count parameters. In this single-center, cross-sectional study, we gathered demographic and clinical data, including blood count parameters, HbA1c values, and CGM metrics, from 128 pediatric subjects with T1D (43% female; mean age, 13.4 ± 3.6 years). Our findings revealed higher levels of the coefficient of variation (CV) (p 250 mg/dL (p = 0.033) among subjects with ΔGMI-HbA1c > 0.3%. No association was observed between blood count parameters and ΔGMI-HbA1c. In conclusion, despite the advancements and the widespread adoption of CGM systems, HbA1c remains an essential parameter for the assessment of glycemic control, especially in individuals with suboptimal metabolic control and extreme glycemic variability.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to evaluate the difference (\(\Delta\)GMI - HbA1c) between the glucose management indicator (GMI) and glycated hemoglobin (HbA1c) in children and adolescents with type 1 diabetes (T1D), and explore the association between this difference and other continuous glucose monitoring (CGM) indicators and blood count parameters. ### Background 1. **Type 1 diabetes (T1D)**: T1D is a chronic disease, and its incidence has been rising in recent years. Due to its characteristic of absolute insulin deficiency, it requires lifelong insulin replacement therapy. 2. **Development of blood - glucose monitoring technology**: With the introduction of insulin pumps and continuous glucose monitoring (CGM) systems, the management of T1D has been significantly improved. These technologies can provide more detailed information on blood - glucose fluctuations, but the blood - glucose control indicators measured by CGM may sometimes be inaccurate. 3. **GMI and HbA1c**: GMI is the HbA1c value estimated based on CGM data, while HbA1c is an important indicator for evaluating long - term blood - glucose control. Although there is a strong correlation between the two, in some cases, differences may occur between them, which requires special attention in clinical practice. ### Research objectives 1. **Evaluate the difference**: Study the difference (\(\Delta\)GMI - HbA1c) between GMI and HbA1c, and divide it into three subgroups: \(\Delta\)GMI - HbA1c ≤ - 0.3%, - 0.3% < \(\Delta\)GMI - HbA1c ≤ 0.3%, \(\Delta\)GMI - HbA1c > 0.3%. 2. **Explore the association**: Analyze the relationship between these differences and other CGM indicators (such as the coefficient of variation of blood - glucose CV, time in target range TIR, time above range TAR, etc.) and blood count parameters. ### Main findings 1. **Significant differences**: More than half of the study subjects (54.7%) showed a GMI and HbA1c difference of at least 0.3%. 2. **High CV and TAR Level2**: In the subgroup with \(\Delta\)GMI - HbA1c > 0.3%, the coefficient of variation of blood - glucose (CV) was higher (38 ± 6.2%), and the proportion of time above 250 mg/dL was also higher (9 ± 8.9%). 3. **No association with blood count parameters**: No significant association was found between blood count parameters and \(\Delta\)GMI - HbA1c. ### Conclusion Although the CGM system has made significant progress in the management of T1D, HbA1c is still an important parameter for evaluating blood - glucose control. Especially in individuals with poor metabolic control and large blood - glucose fluctuations, the interpretation of GMI needs to be cautious. Future more multi - center studies are needed to verify these results and cover more diverse ethnic groups.

Discordance between Glucose Management Indicator and Glycated Hemoglobin in a Pediatric Cohort with Type 1 Diabetes: A Real-World Study